Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity

Stefano Arcangeli, Barbara Alicia Jereczek-Fossa, Filippo Alongi, Cynthia Aristei, Carlotta Becherini, Liliana Belgioia, Michela Buglione, Luciana Caravatta, Rolando Maria D’Angelillo, Andrea Riccardo Filippi, Michele Fiore, Domenico Genovesi, Carlo Greco, Lorenzo Livi, Stefano Maria Magrini, Giulia Marvaso, Rosario Mazzola, Icro Meattini, Anna Merlotti, Isabella PalumboStefano Pergolizzi, Sara Ramella, Umberto Ricardi, Elvio Russi, Marco Trovò, Alessandro Sindoni, Vincenzo Valentini, Renzo Corvò

Research output: Contribution to journalArticle

Abstract

Clinical development and use of novel systemic agents in combination with radiotherapy (RT) is at nowadays most advanced in the field of treatment of solid tumors. Although for many of these substances preclinical studies provide sufficient evidences on their principal capability to enhance radiation effects, the majority of them have not been investigated in even phase I clinical trials for safety in the context of RT. In clinical practice, unexpected acute and late side effects may emerge especially in combination with RT. As a matter of fact, despite combined modality treatment holds potential for enhancing the therapeutic ratio, some concerns are raised from the lack of high-quality clinical data to guide the care of patients who are treated with novel compounds in conjunction with RT. The aim of this review is to provide, from a radio-oncological point of view, an overview of the most advanced combined treatment concepts for solid tumors focusing on treatment toxicity.
Original languageEnglish
JournalCritical Reviews in Oncology/Hematology
DOIs
Publication statusPublished - 2018

Fingerprint

Medical Oncology
Radiotherapy
Neoplasms
Therapeutics
Clinical Trials, Phase I
Radiation Effects
Radio
Patient Care
Safety

Keywords

  • Radiotherapy
  • Systemic compounds
  • Toxicity

Cite this

Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity. / Arcangeli, Stefano; Jereczek-Fossa, Barbara Alicia; Alongi, Filippo; Aristei, Cynthia; Becherini, Carlotta; Belgioia, Liliana; Buglione, Michela; Caravatta, Luciana; D’Angelillo, Rolando Maria; Filippi, Andrea Riccardo; Fiore, Michele; Genovesi, Domenico; Greco, Carlo; Livi, Lorenzo; Magrini, Stefano Maria; Marvaso, Giulia; Mazzola, Rosario; Meattini, Icro; Merlotti, Anna; Palumbo, Isabella; Pergolizzi, Stefano; Ramella, Sara; Ricardi, Umberto; Russi, Elvio; Trovò, Marco; Sindoni, Alessandro; Valentini, Vincenzo; Corvò, Renzo.

In: Critical Reviews in Oncology/Hematology, 2018.

Research output: Contribution to journalArticle

Arcangeli, S, Jereczek-Fossa, BA, Alongi, F, Aristei, C, Becherini, C, Belgioia, L, Buglione, M, Caravatta, L, D’Angelillo, RM, Filippi, AR, Fiore, M, Genovesi, D, Greco, C, Livi, L, Magrini, SM, Marvaso, G, Mazzola, R, Meattini, I, Merlotti, A, Palumbo, I, Pergolizzi, S, Ramella, S, Ricardi, U, Russi, E, Trovò, M, Sindoni, A, Valentini, V & Corvò, R 2018, 'Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity', Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/j.critrevonc.2018.11.006
Arcangeli, Stefano ; Jereczek-Fossa, Barbara Alicia ; Alongi, Filippo ; Aristei, Cynthia ; Becherini, Carlotta ; Belgioia, Liliana ; Buglione, Michela ; Caravatta, Luciana ; D’Angelillo, Rolando Maria ; Filippi, Andrea Riccardo ; Fiore, Michele ; Genovesi, Domenico ; Greco, Carlo ; Livi, Lorenzo ; Magrini, Stefano Maria ; Marvaso, Giulia ; Mazzola, Rosario ; Meattini, Icro ; Merlotti, Anna ; Palumbo, Isabella ; Pergolizzi, Stefano ; Ramella, Sara ; Ricardi, Umberto ; Russi, Elvio ; Trovò, Marco ; Sindoni, Alessandro ; Valentini, Vincenzo ; Corvò, Renzo. / Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity. In: Critical Reviews in Oncology/Hematology. 2018.
@article{405b99acaf7b4209ba6864b8ef5ecca5,
title = "Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity",
abstract = "Clinical development and use of novel systemic agents in combination with radiotherapy (RT) is at nowadays most advanced in the field of treatment of solid tumors. Although for many of these substances preclinical studies provide sufficient evidences on their principal capability to enhance radiation effects, the majority of them have not been investigated in even phase I clinical trials for safety in the context of RT. In clinical practice, unexpected acute and late side effects may emerge especially in combination with RT. As a matter of fact, despite combined modality treatment holds potential for enhancing the therapeutic ratio, some concerns are raised from the lack of high-quality clinical data to guide the care of patients who are treated with novel compounds in conjunction with RT. The aim of this review is to provide, from a radio-oncological point of view, an overview of the most advanced combined treatment concepts for solid tumors focusing on treatment toxicity.",
keywords = "Radiotherapy, Systemic compounds, Toxicity",
author = "Stefano Arcangeli and Jereczek-Fossa, {Barbara Alicia} and Filippo Alongi and Cynthia Aristei and Carlotta Becherini and Liliana Belgioia and Michela Buglione and Luciana Caravatta and D’Angelillo, {Rolando Maria} and Filippi, {Andrea Riccardo} and Michele Fiore and Domenico Genovesi and Carlo Greco and Lorenzo Livi and Magrini, {Stefano Maria} and Giulia Marvaso and Rosario Mazzola and Icro Meattini and Anna Merlotti and Isabella Palumbo and Stefano Pergolizzi and Sara Ramella and Umberto Ricardi and Elvio Russi and Marco Trov{\`o} and Alessandro Sindoni and Vincenzo Valentini and Renzo Corv{\`o}",
year = "2018",
doi = "10.1016/j.critrevonc.2018.11.006",
language = "English",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity

AU - Arcangeli, Stefano

AU - Jereczek-Fossa, Barbara Alicia

AU - Alongi, Filippo

AU - Aristei, Cynthia

AU - Becherini, Carlotta

AU - Belgioia, Liliana

AU - Buglione, Michela

AU - Caravatta, Luciana

AU - D’Angelillo, Rolando Maria

AU - Filippi, Andrea Riccardo

AU - Fiore, Michele

AU - Genovesi, Domenico

AU - Greco, Carlo

AU - Livi, Lorenzo

AU - Magrini, Stefano Maria

AU - Marvaso, Giulia

AU - Mazzola, Rosario

AU - Meattini, Icro

AU - Merlotti, Anna

AU - Palumbo, Isabella

AU - Pergolizzi, Stefano

AU - Ramella, Sara

AU - Ricardi, Umberto

AU - Russi, Elvio

AU - Trovò, Marco

AU - Sindoni, Alessandro

AU - Valentini, Vincenzo

AU - Corvò, Renzo

PY - 2018

Y1 - 2018

N2 - Clinical development and use of novel systemic agents in combination with radiotherapy (RT) is at nowadays most advanced in the field of treatment of solid tumors. Although for many of these substances preclinical studies provide sufficient evidences on their principal capability to enhance radiation effects, the majority of them have not been investigated in even phase I clinical trials for safety in the context of RT. In clinical practice, unexpected acute and late side effects may emerge especially in combination with RT. As a matter of fact, despite combined modality treatment holds potential for enhancing the therapeutic ratio, some concerns are raised from the lack of high-quality clinical data to guide the care of patients who are treated with novel compounds in conjunction with RT. The aim of this review is to provide, from a radio-oncological point of view, an overview of the most advanced combined treatment concepts for solid tumors focusing on treatment toxicity.

AB - Clinical development and use of novel systemic agents in combination with radiotherapy (RT) is at nowadays most advanced in the field of treatment of solid tumors. Although for many of these substances preclinical studies provide sufficient evidences on their principal capability to enhance radiation effects, the majority of them have not been investigated in even phase I clinical trials for safety in the context of RT. In clinical practice, unexpected acute and late side effects may emerge especially in combination with RT. As a matter of fact, despite combined modality treatment holds potential for enhancing the therapeutic ratio, some concerns are raised from the lack of high-quality clinical data to guide the care of patients who are treated with novel compounds in conjunction with RT. The aim of this review is to provide, from a radio-oncological point of view, an overview of the most advanced combined treatment concepts for solid tumors focusing on treatment toxicity.

KW - Radiotherapy

KW - Systemic compounds

KW - Toxicity

U2 - 10.1016/j.critrevonc.2018.11.006

DO - 10.1016/j.critrevonc.2018.11.006

M3 - Article

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -